Transformed migraine is the older clinical term for the transition from episodic migraine to chronic migraine. ICHD-3 replaced the formal diagnosis with the simpler chronic migraine (1.3), but “transformed migraine” remains useful clinically for describing the process — the months-to-years slide from manageable to chronic.

This page covers the typical trajectory, the reversibility, and why catching transformation early matters.

The typical trajectory

The transformation pattern follows a recognisable arc:

  1. Stable episodic baseline — 2–6 migraine days/month, acute medication on those days, life mostly unaffected.
  2. Frequency creep — over months, attacks rise to 7–10 days/month. Acute medication use rises proportionally.
  3. Cross the MOH threshold — acute medications taken on ≥ 10 days/month (triptans) or ≥ 15 days/month (simple analgesics) for 3+ months.
  4. Headache frequency continues to rise — 11–14 days/month, often with persistent low-grade headache between attacks.
  5. Cross the 15-day threshold — formal chronic migraine diagnosis (ICHD-3 1.3).
  6. Steady chronic state — near-daily headache, medication providing diminishing benefit, life substantially affected.

The trajectory often takes 1–3 years. The early stages can be subtle — a “bad year” doesn’t always look like transformation in real time.

What drives transformation

Cohort studies identify several consistent risk factors:

  • Medication overuse — the single most reversible driver. Crossing the overuse threshold often precipitates transformation within months.
  • High baseline frequency — episodic patients with 10–14 monthly headache days have the highest transformation risk.
  • Obesity — independent risk factor in multiple cohorts.
  • Depression and anxiety — psychiatric comorbidity is a real prognostic factor, both as a contributor and a consequence.
  • Snoring / sleep apnea — addressing sleep apnea reduces chronic migraine frequency in patients who have it.
  • Stressful life events — major stress precipitates transformation in many patients.
  • Female sex — slightly higher transformation rate, particularly perimenopause.

The factors compound. A high-frequency episodic patient with untreated sleep apnea, depression, and rising acute medication use is at substantially higher transformation risk than the sum of the individual factors.

The reversibility

The most important clinical fact: transformation is largely reversible. Annual reversion rates:

  • Chronic → episodic: about 25 percent per year with appropriate management.
  • Higher rates when the dominant driver was MOH and is addressed.

The standard reversion approach:

  1. Address medication overuse — typically withdraw the overused medication with supervised tapering or bridge therapy.
  2. Start preventive medication during the withdrawal period so the patient doesn’t recycle back into overuse once headache frequency briefly worsens.
  3. Address comorbidities — sleep apnea evaluation, depression treatment, weight management as relevant.
  4. Behavioural intervention — CBT for migraine has particularly strong evidence in the chronic / transforming population.

Catching it early matters

The earlier in the trajectory you intervene, the less aggressive the intervention needs to be:

  • Stage 1–2 (frequency creep before MOH): preventive medication conversation, often resolved with one good preventive trial.
  • Stage 3–4 (MOH established): structured withdrawal + preventive start. More complex, often requires specialist.
  • Stage 5–6 (full chronic): everything above plus potentially Botox or CGRP antibodies, longer time horizon to reversion.

If your monthly headache count has been rising for 3+ months, the right move is a headache specialist consultation — not “hope it settles down”.

What Hermly surfaces

Hermly’s monthly report and doctor report both show:

  • Attack frequency trend over the past 90 days — visible rising patterns are exactly what flags potential transformation.
  • Acute medication days counted against MOH thresholds.
  • 30-day-doubling alerts in the monthly report when attack count has doubled from the prior month’s baseline.

The reports don’t diagnose transformation (that requires clinical assessment) but they make the trajectory visible. A patient walking into a neurologist visit with “my Hermly report shows my headache days have gone from 4 to 11 over the past 4 months” gets a different conversation than “I think my migraines might be getting worse”.

What this isn’t

Not a self-diagnosis tool — transformation looks similar to several other conditions (medication-induced headache, secondary headache from another cause, new-onset chronic daily headache) that need clinical differentiation. Not a prescription for what intervention is right — the management depends on which driver is dominant in your case.

What it is: a framework for understanding why your migraine might be getting worse and why that’s not necessarily a permanent state.